Trimetazidine does not alter metabolic substrate oxidation in cardiac mitochondria of target patient population.

ABSTRACT:

Background and purpose

Trimetazidine, known as a metabolic modulator, is an anti-anginal drug used for treatment of stable coronary artery disease (CAD). It is proposed to act via modulation of cardiac metabolism, shifting the mitochondrial substrate utilization towards carbohydrates, thus increasing the efficiency of ATP production. This mechanism was recently challenged; however, these studies used indirect approaches and animal models, which made their conclusions questionable. The goal of the current study was to assess the effect of trimetazidine on mitochondrial substrate oxidation directly in left ventricular myocardium from CAD patients.

Experimental approach

Mitochondrial fatty acid (palmitoylcarnitine) and carbohydrate (pyruvate) oxidation were measured in permeabi

SUBMITTER: Cavar M 

PROVIDER: S-EPMC4831310 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature